JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 163 filers reported holding JUNO THERAPEUTICS INC in Q1 2017. The put-call ratio across all filers is 1.30 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $125,087,000 | +59.4% | 2,736,527 | +56.5% | 0.02% | +66.7% |
| Q3 2017 | $78,462,000 | +46.9% | 1,749,038 | -2.1% | 0.01% | +28.6% |
| Q2 2017 | $53,412,000 | +25.5% | 1,786,938 | -6.9% | 0.01% | +40.0% |
| Q1 2017 | $42,574,000 | +17.7% | 1,918,592 | 0.0% | 0.01% | 0.0% |
| Q4 2016 | $36,165,000 | -62.2% | 1,918,592 | -39.8% | 0.01% | -61.5% |
| Q3 2016 | $95,635,000 | -56.4% | 3,186,758 | -44.2% | 0.01% | -56.7% |
| Q2 2016 | $219,386,000 | +0.9% | 5,707,235 | 0.0% | 0.03% | 0.0% |
| Q1 2016 | $217,388,000 | -32.2% | 5,707,235 | -21.7% | 0.03% | -30.2% |
| Q4 2015 | $320,683,000 | +10.7% | 7,293,224 | +2.5% | 0.04% | +4.9% |
| Q3 2015 | $289,608,000 | -17.4% | 7,117,424 | +8.2% | 0.04% | -8.9% |
| Q2 2015 | $350,714,000 | -10.1% | 6,576,290 | +2.3% | 0.04% | -10.0% |
| Q1 2015 | $389,961,000 | +42.6% | 6,428,631 | +22.8% | 0.05% | +38.9% |
| Q4 2014 | $273,396,000 | – | 5,235,467 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Biomark Capital Management Co. LLC | 2,168,601 | $65,080,000 | 86.12% |
| Crestline Management, LP | 17,348,799 | $520,637,000 | 66.02% |
| Omega Fund Management, LLC | 1,229,512 | $36,898,000 | 28.17% |
| SIB LLC | 100,000 | $3,001,000 | 2.42% |
| Clarius Group, LLC | 117,896 | $3,538,000 | 1.65% |
| BB BIOTECH AG | 1,405,000 | $42,164,000 | 1.48% |
| Duquesne Family Office | 493,000 | $14,795,000 | 1.31% |
| First Washington CORP | 65,320 | $1,960,000 | 1.10% |
| PFM Health Sciences, LP | 1,124,285 | $33,740,000 | 0.99% |
| Partner Investment Management, L.P. | 18,376 | $551,000 | 0.82% |